A Novel View of Human Helicobacter pylori Infections: Interplay between Microbiota and Beta-Defensins

Pero, Raffaela; Brancaccio, Mariarita; Laneri, Sonia; Biasi, M.G. De; Lombardo, Barbara; Scudiero, Olga

doi:10.3390/biom9060237

Cited by 41 publications

(45 citation statements)

References 134 publications

(156 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the course of the experiment, the two groups began to separate ( P = .083 at 3 months and P = .006 at 6 months) 48 . This indicated that the time period for acquiring H pylori infection may be another factor in the divergence for microbiome alterations with H pylori infection 49 . Besides, the gut microbiota could be influenced by other factors such as exercise and host genome 50,51 .…”

Section: Discussionmentioning

confidence: 97%

Long‐term changes in the gut microbiota after 14‐day bismuth quadruple therapy in penicillin‐allergic children

Zhou

Miao

et al. 2020

Helicobacter

View full text Add to dashboard Cite

Background Penicillin‐allergic children who are infected with Helicobacter pylori constitute a relatively common subgroup. We aimed to study the short‐term and long‐term effects of bismuth quadruple therapy on gut microbiota in penicillin‐allergic children. Methods We prospectively recruited treatment‐naive children with H pylori infection and H pylori‐negative asymptomatic children as healthy controls. Patients received 14‐day bismuth quadruple therapy consisting of omeprazole, clarithromycin, metronidazole, and bismuth. Fecal samples were collected at weeks 0, 2, 6, and 52. Alterations in the gut microbiota were analyzed by 16S rRNA gene sequencing. Results Twenty‐two subjects (14 gastritis patients, 8 duodenal ulcer patients) and 23 controls participated in this study. At week 2, alpha diversity was reduced in both gastritis (P < .05) and ulcer (except P = .16 with Chao 1 index) patients compared with baseline. Some changes persisted at week 6, and all were restored at week 52. Beta diversity was significantly altered 2 weeks after treatment in the gastritis and duodenal ulcer groups (P = .001, P = .002, respectively) and restored at weeks 6 and 52. The mean relative abundance of Bacteroidetes (P < .001, P = .005, respectively) decreased and that of Proteobacteria increased (P < .001, P = .03, respectively). All alterations recovered at week 6 and 52. In both the gastritis and ulcer groups at week 2, some beneficial bacteria were decreased including Bacteroides (P < .001 and P = .003), Faecalibacterium (P < .001 and P = .02), Phascolarctobacterium (P = .002 and P = .004), Roseburia ( P < .001 and P = .13), Bifidobacterium (P = .08 and P = .04), and Blautia (P < .001 and P = .002). Some detrimental bacteria were increased including Escherichia‐Shigella (P < .001 and P = .19), Klebsiella (P < .001, and P = .09), Enterococcus (P < .001 and P = .007), and Streptococcus (P = .002 and P = .004). The changes returned to almost the pre‐eradication level 1 year after therapy. Conclusion Bismuth quadruple therapy causes short‐term dysbiosis of the gut microbiota. Most changes recovered 1‐year post‐eradication, indicating the long‐term safety of H pylori therapy.

show abstract

Section: Discussionmentioning

confidence: 97%

Long‐term changes in the gut microbiota after 14‐day bismuth quadruple therapy in penicillin‐allergic children

Zhou

Miao

et al. 2020

Helicobacter

View full text Add to dashboard Cite

show abstract

“…The other topic which deserves more attention is HPI-associated dysregulation of gut microbiota [ 239 , 606 , 653 , 654 , 655 , 656 , 657 , 658 , 659 , 660 , 661 , 662 , 663 , 664 , 665 , 666 , 667 ], a phenomenon described also in animal models (infected Mongolian gerbils [ 668 ]) and thought to be due mainly to gut immunopathological/inflammatory responses and suppressed gastric acid secretion following chronic/atrophic gastritis or use of acid-suppressive drugs. Gut dysbiosis by affecting various biological processes contributes to the pathogenesis of OP [ 669 , 670 , 671 , 672 , 673 , 674 , 675 , 676 , 677 , 678 , 679 , 680 , 681 , 682 , 683 , 684 , 685 , 686 , 687 , 688 , 689 , 690 , 691 , 692 , 693 , 694 , 695 , 696 , 697 , 698 , 699 ] as well as to numerous other extra-digestive system diseases associated with OFs [ 700 , 701 , 702 ,…”

Section: Clinical Implications and Recommendationsmentioning

confidence: 99%

Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review)

Fisher

Smith

2020

JCM

View full text Add to dashboard Cite

Osteoporosis (OP) and osteoporotic fractures (OFs) are common multifactorial and heterogenic disorders of increasing incidence. Helicobacter pylori (H.p.) colonizes the stomach approximately in half of the world’s population, causes gastroduodenal diseases and is prevalent in numerous extra-digestive diseases known to be associated with OP/OF. The studies regarding relationship between H.p. infection (HPI) and OP/OFs are inconsistent. The current review summarizes the relevant literature on the potential role of HPI in OP, falls and OFs and highlights the reasons for controversies in the publications. In the first section, after a brief overview of HPI biological features, we analyze the studies evaluating the association of HPI and bone status. The second part includes data on the prevalence of OP/OFs in HPI-induced gastroduodenal diseases (peptic ulcer, chronic/atrophic gastritis and cancer) and the effects of acid-suppressive drugs. In the next section, we discuss the possible contribution of HPI-associated extra-digestive diseases and medications to OP/OF, focusing on conditions affecting both bone homeostasis and predisposing to falls. In the last section, we describe clinical implications of accumulated data on HPI as a co-factor of OP/OF and present a feasible five-step algorithm for OP/OF risk assessment and management in regard to HPI, emphasizing the importance of an integrative (but differentiated) holistic approach. Increased awareness about the consequences of HPI linked to OP/OF can aid early detection and management. Further research on the HPI–OP/OF relationship is needed to close current knowledge gaps and improve clinical management of both OP/OF and HPI-related disorders.

show abstract

“…The third comprises the neutralization of the activity of MprF; as a consequence, there is a decrease in the infectious activity by S. aureus, making it more accessible to treatment with lipopeptide antibiotic daptomycin [131]. In addition, cyclization and analog engineering increase the stability of different AMPs enclosing human defensins [131][132][133][134][135][136][137][138][139][140][141]. This process improves their therapeutic efficacy; as a result, a greater susceptibility by S. aureus is observed, thus causing the disappearance of skin infections.…”

Section: Conclusion and Future Perspectivementioning

confidence: 99%

Human Defensins: A Novel Approach in the Fight against Skin Colonizing Staphylococcus aureus

et al. 2020

View full text Add to dashboard Cite

Staphylococcus aureus is a microorganism capable of causing numerous diseases of the human skin. The incidence of S. aureus skin infections reflects the conflict between the host skin′s immune defenses and the S. aureus’ virulence elements. Antimicrobial peptides (AMPs) are small protein molecules involved in numerous biological activities, playing a very important role in the innate immunity. They constitute the defense of the host′s skin, which prevents harmful microorganisms from entering the epithelial barrier, including S. aureus. However, S. aureus uses ambiguous mechanisms against host defenses by promoting colonization and skin infections. Our review aims to provide a reference collection on host-pathogen interactions in skin disorders, including S. aureus infections and its resistance to methicillin (MRSA). In addition to these, we discuss the involvement of defensins and other innate immunity mediators (i.e., toll receptors, interleukin-1, and interleukin-17), involved in the defense of the host against the skin disorders caused by S. aureus, and then focus on the evasion mechanisms developed by the pathogenic microorganism under analysis. This review provides the “state of the art” on molecular mechanisms underlying S. aureus skin infection and the pharmacological potential of AMPs as a new therapeutic strategy, in order to define alternative directions in the fight against cutaneous disease.

show abstract

A Novel View of Human Helicobacter pylori Infections: Interplay between Microbiota and Beta-Defensins

Cited by 41 publications

References 134 publications

Long‐term changes in the gut microbiota after 14‐day bismuth quadruple therapy in penicillin‐allergic children

Long‐term changes in the gut microbiota after 14‐day bismuth quadruple therapy in penicillin‐allergic children

Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review)

Human Defensins: A Novel Approach in the Fight against Skin Colonizing Staphylococcus aureus

Contact Info

Product

Resources

About